Page 27 - MI-1-2

Microbes & Immunity Homologous versus heterologous COVID-19 vaccines

Table 2. (Continued)
No References Country Study design Vaccine (dose) Median age Groups Number of Intervention Interval
(range) subjects between
doses
66.8 Group C 112 Control
(IQR 51.9 – 78.0) (prime with
64.4 BNT/BNT) 110 BNT half
(IQR 47.7 – 78.2) (homologous)
65.0 111 m1273
(IQR 50.3 – 75.5) (heterologous)
63.4 106 CVn
(IQR 47.3 – 76.6) (heterologous)
20 Normark Sweden Observational ChAd (0.5 mL) 46 (28 – 62) Group 1 37 ChAd/ChAd 9 – 12 weeks
et al., 2021 study (homologous)
25
mRNA-1273 40 (23 – 59) Group 2 51 ChAd/m1273
(0.5 mL) (heterologous)
21 Rose et al., Germany Observational ChAd (0.5 mL) 27 (18 – 56) Group 1 40 ChAd/BNT 10 – 12 weeks
26
2022 study (heterologous)
BNT (0.3 mL) 41 (23 – 61) Group 2 9 ChAd/ChAd 10 – 12 weeks
(homologous)
35 (23 – 51) Group 3 8 BNT/BNT 2 weeks
(homologous)
22 Schmidt Germany Observational ChAd (0.5 mL) 48.6 Group 1 55 ChAd/ChAd 8 – 12 weeks
et al., 2021 study (homologous)
27
BNT (0.3mL) 40.8 Group 2 96 ChAd/mRNA 8 – 12 weeks
(heterologous) (either BNT or
m-1273)
mRNA-1273 44.7 Group 3 62 mRNA/mRNA 3 weeks
(0.5 mL) (homologous)
23 Stuart United RCT ChAd (0.5 mL) 64.4 (50.1 – 74.2) Group 1 180 ChAd/ChAd 8 – 12 weeks
et al., 2022 Kingdom (homologous)
28
BNT (0.3 mL) 64.1 (50.2 – 74.4) Group 2 181 ChAd/m1273
(heterologous)
mRNA-1273 64.2 (50.1 – 74.6) Group 3 179 ChAd/NVX
(0.5 mL) (heterologous)
NVX (0.5 mL) 62.3 (50.4 – 77.1) Group 4 175 BNT/BNT
(homologous)
62.4 (50.0 – 77.7) Group 5 177 BNT/m1273
(heterologous)
62.7 (50.2 – 78.1) Group 6 180 BNT/NVX
(heterologous)
24 Tenbusch Germany Observational ChAd (0.5 mL) 38.7 (20 – 65) Group 1 537 BNT/BNT 2 weeks
et al., 2021 study (homologous)
29
BNT (0. 3mL) 57 (31 – 64) Group 2 66 ChAd/ChAd 9 – 12 weeks
(homologous)
49.6 (18 – 65) Group 3 482 ChAd/BNT 9 – 12 weeks
(heterologous)
25 Vallée France Retrospective, ChAd (0.5 mL) 37 (IQR 24 – 50) Group 1 130 ChAd/BNT 12 weeks
et al., 2021 cross-sectional (heterologous)
30
monocenter BNT (0. 3mL) 32 (IQR 21 – 43) Group 2 67 BNT/BNT 4 weeks
study (homologous)
(Cont’d...)

Volume 1 Issue 2 (2024) 21 doi: 10.36922/mi.3757